Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
721-740 of 847 trials

Advanced Ovarian Cancer: TORL-1-23 Treatment Study

We are studying the effectiveness of TORL-1-23 in women with advanced platinum-resistant ovarian cancer that expresses Claudin 6. This research aims to find new treatment options for this challenging condition.

Peritoneal CancerOvarian CancerFallopian Tube Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Heart Attack Recovery: Ferric Carboxymaltose Treatment

We are studying whether intravenous ferric carboxymaltose can improve survival and quality of life in iron-deficient patients who recently had a heart attack. This trial compares its effects to a placebo treatment.

Recent Heart Attack>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCardiologyInternal Medicine

Higher Risk Myelodysplastic Syndrome: Lisaftoclax with Azacitidine

We are studying whether the combination of Lisaftoclax and azacitidine is more effective than a placebo with azacitidine for adults newly diagnosed with higher risk myelodysplastic syndrome. The trial will also assess safety and patient-reported outcomes.

Higher Risk Myelodysplastic SyndromeConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Juvenile Psoriatic Arthritis: Deucravacitinib Study

We are testing a new medication, deucravacitinib, in children and teens aged 5 to 18 with Juvenile Psoriatic Arthritis. The study aims to see if it works better than a placebo and to ensure it is safe and easy to take.

Systemic Juvenile Idiopathic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsRheumatology

BOTOX® for Preventing Pancreatic Fistula After Surgery

We are studying whether BOTOX® injections before surgery can help prevent complications in patients undergoing distal pancreatectomy. This trial will assess the safety and effectiveness of this approach.

Postoperative Pancreatic Fistulas≤3 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Advanced Liver Cancer: CS1003 with Lenvatinib

We are studying a new treatment combined with lenvatinib for people with advanced liver cancer. The trial compares this combination to a placebo with lenvatinib to see which is more effective and safe.

Unresectable Advanced Liver Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteHepatologyOncology

Scarred Vocal Folds: Autologous Fat Injection Study

We are investigating whether an injection of fat-derived cells can improve voice quality in individuals with scarred vocal folds. This study compares the treatment to a placebo to assess its effectiveness and safety.

Scarred Vocal Folds>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngology

HER2 Mutated Solid Tumors: Sevabertinib Study

We are studying how well sevabertinib tablets work and their safety for patients with solid tumors that have HER2 mutations. This research may help improve treatment options for these patients.

Pancreatic CancerUrothelial CarcinomaGallbladder Cancer6-12 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineOncology

Prostate Cancer: BMS-986365 vs. Standard Treatment

We are comparing a new medication, BMS-986365, to standard treatments for men with metastatic castration-resistant prostate cancer. The study aims to see if the new drug can better delay disease progression and improve overall health.

Metastatic Castration-resistant Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Ovarian Cancer: Relacorilant with Nab-Paclitaxel and Bevacizumab

We are studying a new treatment combination for patients with advanced ovarian, primary peritoneal, or fallopian-tube cancer. The trial aims to evaluate how well this combination works and its safety.

Ovarian, Fallopian Tube, or Peritoneal CancerEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Chronic Inflammatory Demyelinating Polyradiculoneuropathy: TAK-881 vs. HYQVIA

We are comparing two medications to see if TAK-881 works similarly to HYQVIA in adults with CIDP. This study may help determine the best treatment options for managing this condition.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Duchenne Muscular Dystrophy: ENTR-601-45 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Duchenne Muscular Dystrophy6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Chronic Inflammatory Demyelinating Polyneuropathy: DNTH103 Treatment Study

We are studying a new treatment called DNTH103 for adults with Chronic Inflammatory Demyelinating Polyneuropathy. The trial aims to see if it can help reduce relapses and improve overall health compared to a placebo.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Severe Asthma: Tezepelumab Treatment

We are exploring how Tezepelumab may improve airway barrier function in patients with severe asthma, including those with chronic rhinosinusitis. This study looks at the effects of the treatment on the airways' response to harmful substances.

Severe Asthma with Chronic Rhinosinusitis and Nasal PolypsSevere Asthma without Chronic Rhinosinusitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyOtolaryngologyPulmonology

Neovascular Age-Related Macular Degeneration: Faricimab Injections

We are studying the safety and long-term effectiveness of faricimab injections for people with neovascular age-related macular degeneration. The goal is to see if it improves vision and how well it works over time.

Neovascular Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

Severe Asthma: Dupilumab Treatment Study

We are investigating how Dupilumab affects mucus buildup and immune responses in patients with severe asthma. This study aims to improve understanding of asthma management and treatment options.

Severe Asthma>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

Kidney Transplant: Ravulizumab Study

We are testing Ravulizumab in adults at high risk of delayed graft function after kidney transplantation. The goal is to see if it helps improve kidney function and reduces the need for dialysis.

Delayed Graft Function after Kidney Transplantation1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNephrology

Duchenne Muscular Dystrophy: ENTR-601-44 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and how it affects muscle function. Participants will receive either the treatment or a placebo in a controlled setting.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Papillary Craniopharyngioma: Dabrafenib and Trametinib Treatment

We are studying how well the medications dabrafenib and trametinib reduce tumor size in patients with papillary craniopharyngioma. The trial also looks at how these treatments affect quality of life and other health aspects.

Papillary Craniopharyngioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Managing High Potassium: Lokelma for Chronic Kidney Disease

We are studying whether Sodium Zirconium Cyclosilicate (Lokelma) can help lower potassium levels in patients with chronic kidney disease. This trial compares it to standard treatments to find the best approach.

High Potassium Levels in Chronic Kidney Disease3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesInternal MedicineNephrology